Compare · BIO vs SEER
BIO vs SEER
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $10.44B, about 92.4x SEER ($113.0M).
- SEER has been more active in the news (7 items in the past 4 weeks vs 2 for BIO).
- BIO has more recent analyst coverage (12 ratings vs 8 for SEER).
- Company
- Bio-Rad Laboratories Inc.
- Seer Inc.
- Price
- $390.39+2.45%
- $2.05+0.49%
- Market cap
- $10.44B
- $113.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2020
- News (4w)
- 2
- 7
- Recent ratings
- 12
- 8
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest BIO
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Latest SEER
- PRESIDENT & CFO Horn David R. sold $14,809 worth of shares (7,309 units at $2.03), decreasing direct ownership by 1% to 486,650 units (SEC Form 4) to cover taxes
- Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
- SEC Form 10-Q filed by Seer Inc.
- Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
- Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
- Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
- Seer Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Seer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.